GlassScriptPhysician profile
Mark M Cheung
NPI 1639464555
$6,389.17
in general payments reported to CMS, 2019-2025
24 companies · $804 in 2025
The $804 reported for 2025 was more than what 87% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,829 · 2020: $558 · 2021: $1,131 · 2022: $700 · 2023: $832 · 2024: $536 · 2025: $804.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,171.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $1,709.44 | 2019-2023 | Flarex |
| Sun Pharmaceutical Industries INC. | $705.98 | 2019-2025 | Cequa, Xelpros |
| Novartis Pharmaceuticals Corporation | $701.95 | 2019-2023 | |
| Alcon Vision LLC | $508.96 | 2020-2025 | Precision7, Eysuvis, Total30 |
| Coopervision INC. | $436.50 | 2019-2025 | Misight Contact Lens, Myday Contact Lens, Onefit Contact Lens |
| Aerie Pharmaceuticals, INC. | $406.14 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $337.13 | 2023-2025 | Miebo, Vyzulta, Xiidra |
| Visionary Optics LLC | $250.00 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $231.81 | 2025 | Amo Phaco Needle |
| Oyster Point Pharma, INC. | $180.15 | 2022-2024 | Tyrvaya, Ryzumvi |
| Biotissue Holdings INC. | $174.76 | 2023-2025 | |
| Johnson & Johnson Vision Care, INC. | $148.46 | 2019-2023 | Acuvue |
| Allergan, INC. | $111.44 | 2020-2021 | |
| Rxsight INC | $110.15 | 2023 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $85.61 | 2019-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $58.22 | 2022-2024 | Oxervate |
| Shire North American Group INC | $46.65 | 2019 | |
| Kala Pharmaceuticals, INC. | $42.28 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $39.22 | 2024 | Xdemvy |
| Horizon Therapeutics Plc | $29.11 | 2023 | Tepezza |
| Astellas Pharma US INC | $20.08 | 2024 | Izervay |
| Harrow Eye, LLC | $18.83 | 2025 | Vevye |
| Glaukos Corporation | $18.61 | 2024 | Ce-Marked Kxla System |
| Thea Pharma INC. | $17.69 | 2024 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Cheung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.